secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001493152-24-042902
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 3.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics closes $1.1M private placement, exchanges debt for equity, addresses Nasdaq compliance
--------------------------------------------------------------------------------

- Stockholders approved issuance of shares for September 2024 transactions at Oct 29 annual meeting.
- Closed private placement: issued 1,401,994 shares + 115,000 pre-funded warrants; gross proceeds $1.1M.
- Exchange transactions: issued 38,302,029 shares for outstanding warrants and convertible notes.
- Bridge notes converted: 6,244,237 shares + 1,764,000 pre-funded warrants; $0.50 conversion price.
- Post-closing cap: ~51.4M shares outstanding; Nasdaq hearing on Nov 12 to address equity compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315224042902/0001493152-24-042902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315224042902/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer